[go: up one dir, main page]

JO3385B1 - عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه - Google Patents

عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه

Info

Publication number
JO3385B1
JO3385B1 JOP/2012/0324A JOP20120324A JO3385B1 JO 3385 B1 JO3385 B1 JO 3385B1 JO P20120324 A JOP20120324 A JO P20120324A JO 3385 B1 JO3385 B1 JO 3385B1
Authority
JO
Jordan
Prior art keywords
adrenomedullin
polyethylene glycol
glycol based
based prodrug
treat
Prior art date
Application number
JOP/2012/0324A
Other languages
English (en)
Inventor
Knorr Andreas
Redlich Gorden
MARLEY Julie
Köbberling Johannes
Ingo Flamme Dr
Griebenow Nils
Schohe-Loop Rudolf
Wittrock Sven
Wunder Frank
Pritchard Iain
Koellnberger Maria
Lerchen Hans-Georg
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Application granted granted Critical
Publication of JO3385B1 publication Critical patent/JO3385B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)

Abstract

يتعلق الاختراع بعقار معتمد على polyethylene glycol (PEG) جديد من adrenomedullin، بعمليات لتحضيره، باستخدام ذلك لمعالجة و/أو منع أمراض، واستخدام ذلك لإنتاج أدوية من أجل معالجة و/أو منع أمراض، خصوصا اضطرابات قلبية وعائية، أوديمية و/أو التهابية.
JOP/2012/0324A 2011-11-03 2012-10-24 عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه JO3385B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11187735 2011-11-03

Publications (1)

Publication Number Publication Date
JO3385B1 true JO3385B1 (ar) 2019-03-13

Family

ID=47146369

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2019/0001A JOP20190001B1 (ar) 2011-11-03 2011-11-03 عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه
JOP/2012/0324A JO3385B1 (ar) 2011-11-03 2012-10-24 عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JOP/2019/0001A JOP20190001B1 (ar) 2011-11-03 2011-11-03 عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه

Country Status (45)

Country Link
US (3) US9603936B2 (ar)
EP (2) EP3075395B1 (ar)
JP (2) JP5995984B2 (ar)
KR (2) KR101965467B1 (ar)
CN (2) CN103998063B (ar)
AR (2) AR088582A1 (ar)
AU (2) AU2012331244B2 (ar)
BR (1) BR112014010708B1 (ar)
CA (1) CA2854134C (ar)
CL (1) CL2014000948A1 (ar)
CO (1) CO7020863A2 (ar)
CR (1) CR20140184A (ar)
CU (1) CU24184B1 (ar)
CY (2) CY1117354T1 (ar)
DK (2) DK2773376T3 (ar)
DO (2) DOP2014000078A (ar)
EA (2) EA025631B1 (ar)
EC (2) ECSP14013326A (ar)
ES (2) ES2659195T3 (ar)
GT (1) GT201400085A (ar)
HR (2) HRP20160285T1 (ar)
HU (2) HUE036535T2 (ar)
IL (3) IL232037B (ar)
IN (1) IN2014CN03290A (ar)
JO (2) JOP20190001B1 (ar)
LT (1) LT3075395T (ar)
MA (1) MA35618B1 (ar)
ME (1) ME02379B (ar)
MX (2) MX350341B (ar)
MY (2) MY173372A (ar)
NO (1) NO3075395T3 (ar)
PE (2) PE20141219A1 (ar)
PH (1) PH12014500998A1 (ar)
PL (2) PL3075395T3 (ar)
PT (1) PT3075395T (ar)
RS (2) RS56819B1 (ar)
SG (2) SG11201400924TA (ar)
SI (2) SI3075395T1 (ar)
TN (1) TN2014000185A1 (ar)
TR (1) TR201802124T4 (ar)
TW (2) TWI653051B (ar)
UA (1) UA111098C2 (ar)
UY (2) UY37922A (ar)
WO (1) WO2013064508A1 (ar)
ZA (1) ZA201600434B (ar)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150000464A (ko) * 2011-11-03 2015-01-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 펩티드의 방출가능한 연결을 위한 티로신 기재의 링커
EP2896400A1 (en) * 2014-01-17 2015-07-22 Université Catholique De Louvain Method for increasing the bioavailability of inhaled compounds
EP3127914B1 (en) * 2014-03-20 2025-12-17 University of Miyazaki Long-acting adrenomedullin derivatives
KR20170062490A (ko) 2014-09-26 2017-06-07 바이엘 파마 악티엔게젤샤프트 안정화된 아드레노메둘린 유도체 및 그의 용도
SG10202008963QA (en) 2015-09-18 2020-10-29 Univ Miyazaki Long-acting adrenomedullin derivative
CN110678550B (zh) 2017-03-29 2023-11-14 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
GB201707938D0 (en) * 2017-05-17 2017-06-28 Univ Sheffield Compounds
JP2022537369A (ja) 2019-06-18 2022-08-25 バイエル アクチェンゲゼルシャフト 長期安定化のためのアドレノメデュリン－類似体およびその使用
CA3151983A1 (en) * 2019-09-21 2021-03-25 Ozgul TEZGEL Dmso-free synthesis of oligopeptide-modified poly(beta-amino ester)s and their use in nanoparticle delivery systems
JP7498882B2 (ja) * 2019-12-05 2024-06-13 国立大学法人 宮崎大学 異常タンパク質蓄積性神経変性疾患の治療剤
IL297014A (en) * 2020-04-03 2022-12-01 Bayer Ag Pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use
CR20220499A (es) * 2020-04-03 2022-11-18 Bayer Ag Formulaciones farmacéuticas líquidas de profármacos a base de polietilenglicol de adrenomedulina y su uso
IL301285A (en) 2020-09-10 2023-05-01 Precirix N V Antibody fragment against fap
CN112457218B (zh) * 2020-11-05 2022-08-09 宁夏医科大学 2,4-二氨基丁酸衍生物的合成方法
US20240391873A1 (en) 2021-08-20 2024-11-28 Bayer Aktiengesellschaft Process for the preparation of pegylated adrenomedullin, its intermediates and use thereof
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
CA3251753A1 (en) 2022-05-02 2023-11-09 Precirix N.V. PRE-TARGETTING
WO2025133215A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Use of inactive adrenomedullin precursor for therapeutic purposes
WO2025133225A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5020040A (en) * 1987-06-24 1991-05-28 Digital Equipment Corporation Overwriting system for magneto-optical recording with self timing track
US4812590A (en) * 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
CA2292902C (en) 1999-12-24 2012-12-18 Alain Cadieux Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20050271615A1 (en) 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
PT1646813E (pt) 2003-07-23 2013-07-09 Ppg Ind Ohio Inc Vedante compósito e conjunto de janela
HUE045882T2 (hu) 2004-03-23 2020-01-28 Ascendis Pharma Gmbh Polimer prodrug önmagát lehasító linkerrel
WO2005116065A1 (en) 2004-05-24 2005-12-08 Institut De Cardiologie De Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8273325B2 (en) * 2006-12-20 2012-09-25 Ge Healthcare As Contrast agents
EP2155781B1 (en) 2007-05-11 2013-03-13 Institut de Cardiologie de Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy.
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
KR20150000464A (ko) * 2011-11-03 2015-01-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 펩티드의 방출가능한 연결을 위한 티로신 기재의 링커

Also Published As

Publication number Publication date
PL3075395T3 (pl) 2018-04-30
WO2013064508A1 (en) 2013-05-10
ECSP14013326A (es) 2014-05-31
EA201600495A1 (ru) 2016-10-31
RS54623B1 (sr) 2016-08-31
NO3075395T3 (ar) 2018-04-21
US10035818B2 (en) 2018-07-31
KR102004668B1 (ko) 2019-07-26
HK1246147A1 (zh) 2018-09-07
AU2017203423A1 (en) 2017-06-08
UY37922A (es) 2018-11-30
HRP20180319T1 (hr) 2018-03-23
IL258229A (en) 2018-06-28
JOP20190001A1 (ar) 2017-06-16
ECSP18071104A (es) 2018-10-31
EA029410B1 (ru) 2018-03-30
AU2012331244A1 (en) 2014-04-17
IL232037A0 (en) 2014-05-28
EA201400528A1 (ru) 2014-10-30
IL252281A0 (en) 2017-08-31
CR20140184A (es) 2014-05-27
LT3075395T (lt) 2018-02-26
PE20141219A1 (es) 2014-09-13
UY34419A (es) 2013-05-31
US20140287984A1 (en) 2014-09-25
AU2012331244B2 (en) 2017-06-15
CL2014000948A1 (es) 2014-09-05
AU2017203423B2 (en) 2019-01-31
EA025631B1 (ru) 2017-01-30
TWI583396B (zh) 2017-05-21
MX350341B (es) 2017-09-04
CU24184B1 (es) 2016-07-29
CY1119897T1 (el) 2018-06-27
CN103998063B (zh) 2016-09-21
KR20180108892A (ko) 2018-10-04
JP2014532682A (ja) 2014-12-08
CU20140051A7 (es) 2014-10-02
IN2014CN03290A (ar) 2015-07-03
US9649363B2 (en) 2017-05-16
US9603936B2 (en) 2017-03-28
MY173372A (en) 2020-01-21
DK2773376T3 (en) 2016-04-18
KR20150000462A (ko) 2015-01-02
ME02379B (me) 2016-06-20
EP2773376B1 (en) 2016-01-13
EP3075395B1 (en) 2017-11-22
IL258229B (en) 2020-02-27
ES2568063T3 (es) 2016-04-27
HUE027333T2 (en) 2016-09-28
JOP20190001B1 (ar) 2022-03-14
SG11201400924TA (en) 2014-09-26
CN103998063A (zh) 2014-08-20
NZ622997A (en) 2015-12-24
TR201802124T4 (tr) 2018-03-21
TWI653051B (zh) 2019-03-11
SG10201607516SA (en) 2016-10-28
ZA201600434B (en) 2017-05-31
NZ714621A (en) 2017-10-27
US20170204137A1 (en) 2017-07-20
PL2773376T3 (pl) 2016-07-29
CN107412740A (zh) 2017-12-01
SI2773376T1 (sl) 2016-05-31
PH12014500998A1 (en) 2014-06-09
DK3075395T3 (en) 2018-02-19
MX2014004384A (es) 2014-04-30
CA2854134A1 (en) 2013-05-10
IL232037B (en) 2018-12-31
JP5995984B2 (ja) 2016-09-21
EP2773376A1 (en) 2014-09-10
RS56819B1 (sr) 2018-04-30
CN107412740B (zh) 2021-02-09
DOP2014000078A (es) 2014-07-15
PT3075395T (pt) 2018-02-13
CO7020863A2 (es) 2014-08-11
JP6177975B2 (ja) 2017-08-09
PE20181493A1 (es) 2018-09-18
MX361287B (es) 2018-12-03
TN2014000185A1 (en) 2015-09-30
US20160367636A1 (en) 2016-12-22
JP2017014264A (ja) 2017-01-19
CY1117354T1 (el) 2017-04-26
BR112014010708A2 (pt) 2017-04-25
CA2854134C (en) 2020-04-21
TW201720467A (zh) 2017-06-16
KR101965467B1 (ko) 2019-04-03
BR112014010708B1 (pt) 2021-03-02
AR113830A2 (es) 2020-06-17
AR088582A1 (es) 2014-06-18
TW201332573A (zh) 2013-08-16
ES2659195T3 (es) 2018-03-14
SI3075395T1 (en) 2018-03-30
EP3075395A1 (en) 2016-10-05
GT201400085A (es) 2015-03-05
DOP2018000203A (es) 2018-10-15
HUE036535T2 (hu) 2018-07-30
UA111098C2 (uk) 2016-03-25
MA35618B1 (fr) 2014-11-01
HRP20160285T1 (hr) 2016-04-22
IL252281B (en) 2021-01-31
MY194197A (en) 2022-11-21

Similar Documents

Publication Publication Date Title
JO3385B1 (ar) عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه
MX346224B (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
PH12016500094A1 (en) Autotaxin inhibitors
MX380147B (es) Formas de dosificacion de ruxolitinib de liberacion sostenida.
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
WO2012174158A3 (en) Administration of benzodiazepine
UA107550C2 (uk) Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
PH12017500563A1 (en) Stabilized adrenomedullin derivatives and use thereof
CY1120545T1 (el) Συνθεση για τη θεραπεια της διαταραχης μειωμενης σεξουαλικης επιθυμιας
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
UA116011C2 (uk) Частинки фенілефрину резинату та їх використання у фармацевтичних композиціях
PH12020500472A1 (en) Autotaxin inhibitor compounds
IN2013MU03429A (ar)